Studies on the Synthesis of Vitamin D Analogs with Aromatic D-Ring by Eduardo Canosa, Silvina Laura et al.
An Acad Bras Cienc (2018) 90 (1 Suppl. 2)
Anais da Academia Brasileira de Ciências (2018) 90(1 Suppl. 2): 1035-1042
(Annals of the Brazilian Academy of Sciences)
Printed version ISSN 0001-3765 / Online version ISSN 1678-2690
http://dx.doi.org/10.1590/0001-3765201820170701
www.scielo.br/aabc  |  www.fb.com/aabcjournal
Studies on the Synthesis of Vitamin D Analogs with Aromatic D-Ring
SILVINA EDUARDO-CANOSA, MARÍA MARCO, RITA SIGÜEIRO and ANTONIO MOURIÑO
Laboratorio de Investigación Ignacio Ribas, Departamento de Química Orgánica, Universidad de 
Santiago de Compostela, Avda. Ciencias, s/n, 15782 Santiago de Compostela, Spain
Manuscript received on September 6, 2017; accepted for publication on October 10, 2017
ABSTRACT
Herein, we describe our studies on the synthesis of 1α,25-dihydroxyvitamin D3 analogs possessing a 
benzene ring replacing the natural 5-membered D-ring by the Wittig-Horner and dienyne approaches. A key 
feature is the synthesis of a Cr(CO)3-complexed previtamin D derivative that enables the construction of 
vitamin D analogs with aromatic D-ring through a thermal [1,7]-H sigmatropic shift. This study establishes 
the basis for the design of new vitamin D analogs containing aromatic D-ring, complexed or uncomplexed 
to Cr(CO)3 type moieties for specific molecular recognition and drug research and development.
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INTRODUCTION
1α,25-Dihydroxyvitamin D3 [1, 1,25D, calcitriol, 
Figure 1], the most potent steroid hormone known 
and the active metabolite of the seco-steroid 
vitamin D3, interacts with the vitamin D nuclear 
receptor (VDR), a member of the nuclear receptor 
superfamily, to dimerize with the retinoid X receptor 
(RXR). The heterodimer binds to the vitamin D 
response elements (VDREs) in target gene promoters 
and recruit coactivator proteins to induce a cascade 
of events including control of mineral homeostasis 
and various important cellular processes such 
as differentiation, anti-proliferation, growth, 
angiogenesis, apoptosis, and immunomodulation 
(Norman et al. 1979, Evans et al. 1988, Kliewer 
et al. 1992, Bouillon et al. 1995, Feldman et al. 
2011). Recently, it was discovered that 1,25D 
activates more than 229 genes associated with 
several diseases, including arthritis, diabetes and 
cancer, suggesting that this hormone might have 
an even broader range of biological functions than 
originally thought (Lincoln et al. 2010) 1,25D itself 
has clinical applications, but the pharmacological 
doses required for treatment of cancer induce 
strong, undesired hypercalcemia (Plum et al. 2010, 
Feldman et al. 1997). Structure-function studies 
of numerous 1,25D analogs have shown that the 
undesired calcemic effects can be reduced during 
cell-differentiating activities, but the mechanism of 
this selectivity has not yet been unraveled (Feldman 
et al. 2011, Glebocka et al. 2012). Increasing 
synthetic efforts have been directed at the 
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development of non-calcemic analogs of the natural 
hormone 1,25D for treatment of specific disorders, 
but only a few have found clinical applications. 
Among these, calcipotriol (2, Figure 1) and OCT 
(3), two analogs with structural modifications at 
the side chain, are being successfully used for 
treatment of psoriasis (Feldman et al. 1997). A 
few structural features that reduce the calcemic 
activity include: a) unsaturations at the side chain 
or D-ring (Verlinden et al. 2000), b) the lack of 
the 19-methylene group (Kensler et al. 2000), c) 
14-epi-configuration (Verlinden et al. 2000, Ma 
et al. 2013), d) 3-epi-configuration (Molnar et al. 
2011), e) short non-hydroxylated side chains (Plum 
et al. 2004), f) CD-carboranic mimics (Yamada et 
al. 2014) and g) o-carboranic side chains (Otero 
et al. 2016). Nonsecosteroidal vitamin D receptor 
modulators that reduce calcemic effects have also 
been reported (Eduardo-Canosa et al. 2010).
Our continued interest in the synthesis of 
1,25D analogs with selective properties as potential 
drugs for treatment of cancer and/or psoriasis led 
us to study the synthesis of aromatic compounds 4a 
and 4b (Figure 1) as models, which bear a benzene 
ring replacing the natural 5-membered D-ring. 
Preliminary studies to build the triene system of 
4 utilizing the Wittig-Horner coupling approach 
(route A) (Lythgoe 1980) between phosphine-
oxide-lithium anion 5 and ketone 6 resulted in the 
recovery of starting ketone presumably through 
the corresponding enolate (Figure 2). Attempts 
to synthesize 4b through the dienyne approach 
(route B) (Castedo et al. 1986) were hampered by 
difficulties to accomplish the sigmatropic [1,7]-H 
shift on the previtamin 7, presumably due to cross-
conjugation of the triene system with the aromatic 
ring. Here we describe our efforts to synthesize 
4a through route A and 4b through route B, 
from ketone-Cr(CO)3 complex 9. Complexation 
with Cr(CO)6 was envisioned as a way to reduce 
conjugation of the aromatic ring with either the 
carbonyl group in tetralone 6 or the triene system 
in 7. 
MATERIALS AND METHODS
GENERAL MATERIALS AND METHODS
Reagents were purchased from Aldrich Chemical 
(www.sigma-aldrich.com) or Acros Organics 
(www.acros.com) and used without further 
purification. All reactions involving oxygen or 
moisture sensitive compounds were carried out 
under dry argon atmosphere using oven-dried or 
flame-dried glassware and standard syring/septa 
tecniques. All dry solvents were distilled under 
argon immediately prior to use: Tetrahydrofuran 
(THF), Et2O and n-Bu2O were distilled from Na/
benzophenone. CH2Cl2 and Ac2O were distilled 
from P2O5. Hexanes, n-heptane, diisopropilamine 
(i-PrNH2) and triethylamine (Et3N) were distilled 
from CaH2. MeOH was distilled from Mg/I2. DMSO 
was distilled from CaH2 and stored over activated 
4 Å molecular sieves. Solutions of n-butyllithium 
Figure 2 - Retrosynthesis of target 4 by the Wittig-Horner and 
Dienyne approaches.
Figure 1 - Structures of 1,25D (1), calcipotriol (2), OCT (3) 
and target D-ring-aromatic compound 4.
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in hexanes were titrated with N-benzylbenzamide 
before use. Hexanes refer to a distilled mixture 
of hexane isomers. Reaction temperatures refer 
to external bath temperatures. Acetone-dry ice 
baths were used for reactions at low temperature. 
Alternatively, acetone baths were cooled with a 
CRYOCOOL immersion cooler, provided with a 
temperature regulator. Organic extracts were dried 
over anhydrous Na2SO4, filtered and concentrated 
using rotary evaporator at aspirator pressure 
(20−30 mmHg). Sat refers to aqueous saturated 
solution. Reactions were monitored by thin-layer 
chromatography (TLC) using aluminum-backed 
Merck 60 silica gel plates (0.2 mm thickness). After 
visualization under ultraviolet light at 254 nm, the 
plates were developed by immersion in a solution 
containing either a mixture of p-anisaldehyde 
(2.5%), acetic acid (1%), and sulfuric acid (3.4%) 
in 95% ethanol or a solution of ceric ammonium 
nitrate (0.5 g) and ammonium molybdate (4.8 g) 
in H2O (100 mL) and H2SO4 (5.6 mL) followed 
by heating with a heater gun. Flash column 
chromatography was performed with Merck 
silica gel (230−400 mesh). HPLC purifications 
were performed on a Shimadzu preparative liquid 
chromatograph, model LC- 8A, equipped with a 
TSP 1100 UV absorbance detector using a HPLC 
Phenomenex-Luna silica column (Ø 25 x 250 mm 
5Å~ 10 mm). NMR spectra were recorded in CDCl3 
solutions on a Bruker AMX 500 MHz, Varian Inova 
400 MHz or Bruker DPX 250 MHz. Chemical shifts 
are reported on the δ scale (ppm) downfield from 
tetramethylsilane (δ = 0.0 ppm) using the residual 
solvent signal at δ = 7.26 ppm (1H, CDCl3) or 
δ = 77.0 ppm (13C, t, CDCl3) as internal standard; 
coupling constants (J) are reported in Hz. 
Distortionless enhancement by polarization transfer 
(DEPT-135) was used to assign carbon types. Low 
(MS) and high resolution mass spectra (HRMS) 
were performed in a Micromas Instruments 
Autospec spectrometer. 
SYNTHESIS
1,2,3,4-Tetrahydronaphthalen-1-ol (10). NaBH4 
(0.850 g, 22.45 mmol, 1.16 equiv) was added in 
one portion to a -78 ºC cooled solution of ketone 6 
(2.83 g, 19.35 mmol, 1 equiv) in MeOH (85 mL). 
The mixture was allowed to reach 23 ºC and then 
concentrated in vacuo. The residue was dissolved 
in CH2Cl2 (40 mL) and washed with sat NaCl (30 
mL). The organic phase was dried, filtered and 
concentrated in vacuo. The residue was purified 
by flash chromatography (10% EtOAc/hexanes) 
to give alcohols 10 (Zhao et al. 2012) [2.810 g, 
18.96 mmol, 98%, colorless oil, Rf = 0.56 (40% 
EtOAc/hexanes)]. 1H-NMR (250 MHz, CDCl3): δ 
7.46 (1H, m), 7.25 (2H, m), 7.16 (1H, m), 4.78 (1H, 
m), 2.81 (2H, m), 2.33 (1H, s), 2.11-1.73 (4H, m). 
13C-NMR (63 MHz, CDCl3): δ 138.7 (C), 137.0 
(C), 128.8 (CH), 128.6 (CH), 127.4 (CH), 126.0 
(CH), 67.9 (CH, C-1), 32.1 (CH2), 29.1 (CH2), 18.7 
(CH2).
Tricarbonyl [η6-(1,2,3,4-tetrahydronaftalen-
1-ol)] chromium(0) (11). Alcohol 10 (0.100 g, 
0.67 mmol, 1.5 equiv) and Cr(CO)6 (0.222 g, 1.01 
mmol, 1 equiv) were dissolved in a mixture of 
n-Bu2O/n-heptane (8 mL, 1:1). The solution was 
deoxygenated. A stream of argon was passed 
through the solution. Dry THF (0.4 mL) was added. 
The reaction mixture was heated at reflux in the 
dark for 54 h. The mixture was allowed to reach 
23 ºC and filtered through a pad of celite. The 
solids were washed with CH2Cl2 and the combined 
solution was concentrated in vacuo. The residue 
was purified by flash chromatography (50% 
CH2Cl2/hexanes) to give 11 (Schmalz et al. 1992) 
[74 mg, 0.26 mmol, 39%, yellow solid, Rf = 0.20 
(EtOAc/CH2Cl2/hexanes, 1:10:10)] and starting 
material 10 [40 mg, 0.27 mmol, 40%]. 1H-NMR 
(250 MHz, CDCl3): δ 5.81 (1H, d, J = 6.5 Hz), 
5.49 (1H, t, J = 6.2 Hz), 5.09 (2H, m), 4.49 (1H, 
m), 2.84-2.50 (2H, m), 2.23-1.85 (2H, m), 1.79-
1.61 (2H, m). 13C-NMR (63 MHz, CDCl3): δ 233.3 
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(3xC, Cr(CO)3), 113.8 (C), 112.7 (C), 95.1 (CH), 
93.4 (CH), 90.1 (CH), 88.9 (CH), 66.6 (CH, C-1), 
32.2 (CH2), 27.5 (CH2), 19.2 (CH2).
Tricarbonyl-[η6-(3,4-dihydronaftalen-
1(2H)-one)] chromium(0) (9). A solution of 
alcohol 11 (0.600 g, 2.11 mmol) in Ac2O (9 mL) 
and DMSO (13.5 mL) was stirred at 23 ºC for 
3.5 h. The reaction mixture was poured into a 0 
ºC cooled solution of NaOH (250 mL, 10%). The 
resulting mixture was extracted with Et2O (3x30 
mL). The combined organic layers were dried, 
filtered and concentrated in vacuo. The residue 
was purified by flash chromatography [EtOAc/
CH2Cl2/hexanes (1:10:10)] to give ketone 9 
[0.500 g, 1.77 mmol, 84%, orange solid, Rf = 0.44 
(EtOAc/CH2Cl2/hexanes, 1:10:10)]. 
1H-NMR (250 
MHz, CDCl3): δ 6.15 (1H, d, J = 6.6 Hz), 5.62 
(1H, t, J = 6.1 Hz), 5.28 (1H, t, J = 6.3 Hz), 5.14 
(1H, d, J = 5.4 Hz), 2.95 (1H, m), 2.71 (2H, dt, 
J1= 16.8 Hz, J2= 4.1 Hz), 2.43 (1H, m), 2.12 (2H, 
m). 13C-NMR (63 MHz, CDCl3): δ 230.7 (3xC, 
Cr(CO)3), 196.0 (CO, C-1), 115.4 (C), 94.8 (CH), 
92.6 (C), 91.2 (CH), 89.8 (CH), 89.2 (CH), 37.7 




chromium(0) (12). A solution of n-BuLi in hexanes 
(0.69 mL, 1.46 mmol, 2.1M, 2.7 equiv) was slowly 
added to a -78 ºC cooled solution of 5 (1.10 g, 
1.65 mmol, 3 equiv) in dry THF (20 mL). After 
1 h, a solution of 9 (0.155 g, 0.55 mmol, 1 equiv) 
in dry THF (8 mL) was added via cannula. The 
reaction mixture was allowed to reach 15 ºC. H2O 
(0.5 mL) were added. The mixture was concentrated 
in vacuo. The residue was dissolved in Et2O (30 
mL) and successively washed with sat NaHCO3 
(30 mL) and sat NaCl (30 mL). The combined 
aqueous layers were re-extracted with Et2O (3x20 
mL). The combined organic extracts were dried, 
filtered and concentrated in vacuo. The residue 
was purified by flash chromatography (10% 
EtOAc/hexanes) to give a mixture of compounds 
12 and 13 (40 mg) and the starting material 9 (99 
mg, 0.35 mmol, 64%). The mixture of 12 and 13 
was purified by preparative HPLC (hexanes) to 
afford four diasteroisomers: 12a (3 mg, 4 μmol, 
0.7%), 12b (24 mg, 0.03 mmol, 5.5%), 13a (2 mg, 
2.7 μmol, 0.5%) and 13b (7 mg, 0.01 mmol, 1.7%). 
Compound 12b: 1H-NMR (500 MHz, CDCl3): δ 
6.96 (1H, d, J = 11.1 Hz), 6.24 (1H, d, J = 11.1 
Hz), 5.60 (1H, m), 5.45 (1H, s), 5.30-5.24 (3H, 
m), 5.00 (1H, s), 4.60 (1H, m), 4.37 (1H, m), 2.78 
(1H, dt, J1= 9.2 Hz, J2= 4.4 Hz), 2.68-2.53 (3H, 
m), 2.43-2.30 (2H, m), 2.08 (1H, m), 1.93-1.82 
(3H, m), 1.15-1.03 (42H, m). 13C-NMR (75 MHz, 
CDCl3): δ 233.5 (3xC, Cr(CO)3), 149.2 (C), 142.3 
(C), 128.8 (C), 122.5 (CH), 122.4 (CH), 111.8 
(CH2), 109.5 (C), 106.6 (C), 93.8 (CH), 91.5 (CH), 
91.2 (CH), 87.1 (CH), 71.1 (CH), 67.8 (CH), 46.1 
(CH2), 45.1 (CH2), 29.4 (CH2), 25.7 (CH2), 22.0 
(CH2), 18.2 (6xCH3), 18.1 (6xCH3), 12.4 (3xCH), 
12.3 (3xCH). MS ([CI]+, m/z, %): 730 ([M]+, 10), 
687 ([M-iPr]+, 32), 594 ([M-Cr(CO)3]
+, 70), 557 
([M-OTIPS]+, 84), 247 [M-H-2xOTIPS-Cr(CO)3]
+, 
100). HMRS ([CI]+): calcd for: [C40H62CrO5Si2]
+ 
([M]+): 730.3541; found: 730.3550.  Compound 
13b: 1H-NMR (500 MHz, CDCl3): δ 6.45 (1H, d, J 
= 11.2 Hz), 6.40 (1H, d, J = 11.1 Hz), 5.79 (1H, d, J 
= 6.3 Hz), 5.40 (1H, s), 5.35 (1H, m), 5.28 (2H, m), 
4.99 (1H, s), 4.59 (1H, m), 4.37 (1H, m), 2.69 (2H), 
2.58 (1H, d, J = 13.0 Hz), 2.45 (1H, m), 2.39 (2H, 
m), 2.01 (2H, m), 1.89 (1H, m), 1.81 (1H, m), 1.16-
0.99 (42H, m). 13C-NMR (75.47 MHz, CDCl3): δ 
233.3 (3xC, Cr(CO)3), 148.6 (C), 141.9 (C), 130.9 
(C), 126.2 (CH), 123.5 (CH), 112.1 (CH2), 110.3 
(C), 107.0 (C), 94.1 (CH), 92.6 (CH), 92.5 (CH), 
90.1 (CH), 71.0 (CH), 67.8 (CH), 45.8 (CH2), 45.0 
(CH2), 34.0 (CH2), 28.2 (CH2), 23.2 (CH2), 18.2 
(6xCH3), 18.1 (6xCH3), 12.4 (3xCH), 12.3 (3xCH).
Tr i c a r b o n y l - { η 6 - [ 3 , 4 - d i h y d r o - 1 -
((trifluoromethanesulfonyl)oxy)naftalen]} 
chromium(0) (14). 
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A solution of lithium diisopropylamide was 
prepared by slowly addition of a solution of n-BuLi 
in hexanes (0.42 mL, 0.92 mmol, 2.2M, 1.3 equiv) 
to a-78 ºC cooled neat i-Pr2NH (0.14 mL, 1.01 
mmol, 1.4 equiv). The bath was removed and the 
white slurry was stirred at 23 ºC for 15 min. The 
suspension was cooled to -78 ºC and dry THF (2.5 
mL) was added. After 15 min, a solution of ketone 9 
(0.200 g, 0.71 mmol, 1 equiv) in dry THF (2 mL) was 
added dropwise. The reaction mixture was stirred at 
 -78 ºC for 45 min and a solution of N,N-(5-
chloropyridin-2-yl)-bistriflimide (0.444 g, 1.13 
mmol, 1.6 equiv) in dry THF (1.5 mL) was added via 
cannula. The mixture was allowed to reach 23 ºC. 
The reaction was quenched by the addition of H2O 
(10 mL). The mixture was extracted with EtOAc 
(3x10 mL). The combined organic layers were 
dried, filtered and concentrated. The residue was 
purified by flash chromatography (10% EtOAc/
hexanes) to give 14 [0.215 g, 0.52 mmol, 73%, 
orange oil, Rf = 0.44 (20% EtOAc/hexanes)]. 
1H-NMR (250 MHz, CDCl3): δ 6.02 (1H, m), 5.55 
(1H, m), 5.12-5.38 (3H, m), 2.85 (1H, m), 2.40-
2.72 (3H, m). 13C-NMR (63 MHz, CDCl3): δ 232 
(3xC, Cr(CO)3), 124.3 (CH), 120.1 (C), 107.5 
(C), 95.7 (C), 92.0 (CH), 91.4 (CH), 89.9 (CH), 
86.7 (CH), 25.6 (CH2), 21.5 (CH2). MS ([CI]
+, 
m/z, %): 415 ([M+H]+, 97), 414 ([M]+, 98), 279 
([M+H-Cr(CO)3]
+, 43), 266 ([M+H-OTf]+, 96), 147 
(100). HMRS ([CI]+): calcd for: [C14H10O6F3SCr]
+ 
([M+H]+): 414.9555; found: 414.9559.
Tricarbonyl-{η6-(1,2-dihydro-4-[(3S,5R)-
3 ,5 -b i s - ( t e r t -buty ld imethy l s i ly loxy) -2 -
methyl-cyclohex-1-en-1-yl]ethynyl)-naftalen} 
chromium(0) (16). Compound 15 (0.120 g, 0.31 
mmol, 1.3 equiv), PdCl2(PPh3)2 (8 mg, 0.011 mmol, 
5 mol%) and CuI (2 mg, 0.011 mmol, 5 mol%) 
were successively added to a solution of 14 (0.100 
g, 0.24 mmol, 1 equiv) in dry Et3N (3 mL). The 
reaction mixture was heated at 60 °C for 2 h. The 
mixture was allowed to reach 23 ºC and then filtered 
through a pad of celite. The solids were washed 
with CH2Cl2 (3x5 mL) and the combined solution 
was washed with a sat NH4Cl (20 mL). The aqueous 
layer was extracted with CH2Cl2 (3x25 mL). The 
combined organic extracts were dried, filtered and 
concentrated in vacuo. The residue was purified by 
flash chromatography (hexanes) to give 16 [0.121 
g, 0.187 mmol, 78%, orange oil, Rf = 0.60 (20% 
EtOAc/hexanes)]. 1H-NMR (250 MHz, CDCl3): δ 
6.43 (1H, dd, J1 = 6.0 Hz, J2 = 3.7 Hz), 5.82 (1H, 
dd, J1 = 6.0 Hz, J2 = 2.2 Hz), 5.45-5.20 (3H, m), 
4.24 (1H, m), 4.14 (1H, m), 2.86-2.35 (5H, m), 
2.14 (1H, m), 1.98 (3H, s), 1.87 (1H, m), 1.72 (1H, 
m), 0.92 (9H, s), 0.90 (9H, s), 0.12 (6H, br s), 0.08 
(6H, s). 13C-NMR (63 MHz, CDCl3): δ 233.2 (3xC, 
Cr(CO)3), 142.6 (C), 136.7 (CH), 118.9 (C), 114.7 
(C), 107.5 (C), 102.2 (C), 92.5 (CH), 92.1 (C), 91.5 
(CH), 91.2 (CH), 90.7 (CH), 87.2 (C), 69.8 (CH), 
64.1 (CH), 41.1 (CH2), 39.4 (CH2), 26.0 (CH2), 
25.9 (3xCH3), 25.8 (3xCH3), 23.4 (CH2), 19.3 
(CH3), 18.1 (C), 18.0 (C), -4.3 (CH3), -4.6 (CH3), 
-4.7 (CH3), -4.8 (CH3). MS ([CI]
+, m/z, %): 644 
([M]+, 13), 560 ([M-3xCO]+, 8), 377 ([M-OTBS-
Cr(CO)3]
+, 83), 245 [M-H-2TBSO-Cr(CO)3]
+, 
100). HMRS ([CI]+): calcd for: [C34H48CrO5Si2]
+ 




(17). A suspension of quinoleine in hexanes (50 
mL, 2 mmol, 0.04M, 1.25 equiv) and Lindlar 
catalyst (167 mg, Pd/CaCO3 poisoned with lead) 
were successively added to a solution of enyne 16 
(0.100 g, 0.16 mmol, 1 equiv) in dry hexanes (27 
mL). The system was purged three times with argon 
and two times with hydrogen. The reaction mixture 
was stirred under hydrogen at balloon pressure for 
1 h and then filtered through a pad of celite. The 
solids were washed with hexanes and the combined 
solution was concentrated in vacuo. The residue 
was purified by flash chromatography (hexanes) 
to give 16 [0.036 g, 0.06 mmol, 35%, red oil, 
Rf = 0.70 (20% EtOAc/hexanes)].  
1H-NMR (250 
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MHz, CDCl3): δ 6.24 (1H, d, J = 12.1 Hz), 6.04 
(1H, br s), 5.49-5.19 (5H, m), 4.32-3.85 (2H, m), 
2.90-1.20 (11H, m), 0.88 (18H, m), 0.05 (12H, m). 
MS ([CI]+, m/z, %): 510 ([M-Cr(CO)3]
+, 20), 
379 ([M-Cr(CO)3-OTBS]
+, 86), 355 (49), 247 
([M-H-2TBSO]+, 100). HMRS ([CI]+): calcd 
for: [C34H50CrO5Si2]







4-methyl-4-cyclohexene (7). A solution of 17 
(0.030 g, 0.046 mmol) in dry isooctane (5 mL) was 
heated at reflux for 2 h. The reaction was allowed 
to reach 23 ºC and then concentrated in vacuo. The 
residue was re-dissolved in MeOH (3 mL). The 
resulting solution was cooled at 0 ºC and a solution 
of CAN [ammonium cerium(IV) nitrate] in MeOH 
(1.5 mL) was added until green color remained. 
The mixture was extracted with hexanes (3x5 
mL). The combined organic extract was washed 
with H2O (10 mL), dried, filtered and concentrated 
in vacuo. The residue was purified by flash 
chromatography (5% EtOAc/hexanes) to afford a 
mixture of compounds 4b and 7 [0.016 g, 0.031 
mmol, 68%, ca 1:0.7, colorless oil, Rf = 0.70 (5% 
EtOAc/hexanes)]. 1H-NMR (250 MHz, CDCl3): δ 
7.54 (H15-4b, d, J = 7.7 Hz), 7.22-7.04 (Hs-Ar, 
br m), 6.99 (H7-4b, d, J = 11.3 Hz), 6.34 (H6-4b, d, 
J = 11.3 Hz), 6.21 (H7 + H6-7, d, J = 12.2 Hz), 5.98 
(H9-7, t, J = 4.7 Hz), 5.31 (H19-4b, s), 4.95 (H19-
4b, d, J = 2.2 Hz), 4.46 (H1-4b, m), 4.30-3.89 (H3-
4b, H1-7, H3-7, m), 2.88-1.50 (Hs-4+7, m), 0.93-
0.78 (t-BuSi + Me19-7, m), 0.14-0.03 (MeSi, m).
RESULTS AND DISCUSSION
Complex 9 was prepared according to Schmalz’s 
procedure (Figure 3) (Schmalz et al. 1992). 
Reduction of ketone 6 with sodium borohydride 
in methanol provided alcohol 10 in 98% yield. 
Heating at reflux a mixture of 10 and chromium 
hexacarbonyl in n-heptane/n-Bu2O/THF (10:10:1) 
gave the diastereomeric alcohols 11 in 39% yield, 
which upon oxidation with Ac2O and DMSO 
produced the desired Cr(CO)3-complex 9 in 84% 
yield. Wittig-Horner coupling between ketone 9 and 
phosphine oxide anion 5 in THF furnished a mixture 
of four diastereomers (12+13), which could be 
separated by HPLC [12 (two diastereomers 0.7% + 
5.5%); 13 (two distereomers 0.5 + 1.7%)] together 
with recovered starting ketone 9 (64%). Each pair 
of diastereomers could not be distinguished by 
1H NMR (500 MHz). The H7 and H15 of 12 appear 
deshielded with respect to those corresponding 
to 13 (steroid numbering is used for discussion). 
The structure 12 was established by 1H NMR nOe 
analysis.
Though the Cr(CO)3-complexation reduces 
conjugation of the aromatic unit with the carbonyl 
group, the yield on Wittig-Horner reaction products 
is still too low to considerer this approach of 
preparative value. This result led us to examine 
the dienyne approach (route B, Figure 2) as an 
alternative pathway to the target compound 4b 
(Figure 4). Treatment of ketone 9 with LDA 
followed trapping of the resulting enolate with 
2-[N,N-bis(trifluoromethylsulfonyl)-amino]-5-
chloropyridine afforded vinyl triflate 14 (73%), 
which upon Sonogashira coupling (Sonogashira et 
al. 1998) with enyne 15 in the presence catalytic 
amounts of CuI and PdCl2(PPh3)2 provided the 
dienyne 16 (68%). Semihydrogenation of the 
triple bond in the presence of Lindlar catalyst and 
quinoline in hexanes gave the previtamin D 17 
in 35% yield. Finally, thermal sigmatropic [1,7]-
H shift on 17 in refluxing isooctane followed 
by Cr(CO)3-decomplexation with ammonium 
cerium(IV) nitrate in methanol gave a 1:0.7 
mixture of the target protected vitamin 4b and 
the corresponding previtamin 7 in 68% yield. The 
formation of the previtamin 7 can be rationalized 
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by vitamin D-previtamin D equilibration during 
thermal sigmatropic rearragement. Deprotection 
of 4b (TBAF, THF) gave the corresponding 
vitamin D compound (95%), which equilibrates 
with its previtamin D form on standing in CDCl3 
as determined by 1H-NMR (vitamin D/previtamin 
D ratio = 1/2.2, equilibration time = 120 h, room 
temperature).
CONCLUSIONS
In summary, we have demonstrated that the dienyne 
route is suitable for the synthesis of vitamin 
D analogs with aromatic D-ring for biological 
evaluation. The key feature of the synthesis is 
the complexation of the aromatic D-ring with 
Cr(CO)3 to partially release conjugation with 
the previtamin triene system, thus allowing the 
thermal sigmatropic [1,7]-H shift to generate the 
desired vitamin D form. The formation of Cr(CO)3-
complexed vitamin D derivatives opens the way to 
a novel class of VDR-ligands for biological testing. 
(Spectral data (1H and 13C NMR) of all 
compounds - Supplementary Material)
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